Read the full Annual Report in PDF format - CSIR
Read the full Annual Report in PDF format - CSIR
Read the full Annual Report in PDF format - CSIR
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Interests of <strong>the</strong> <strong>CSIR</strong><br />
Net <strong>in</strong>debtness less accumulated impairment losses Net <strong>in</strong>vestment General nature of bus<strong>in</strong>ess<br />
to subsidiaries by subsidiaries<br />
2011 2010 2011 2010 2011 2010<br />
R’000 R’000 R’000 R’000 R’000 R’000<br />
- - 12 000 13 262 16 650 17 912 The acquisition and transfer of technology to<br />
<strong>in</strong>dustry by licens<strong>in</strong>g new <strong>in</strong>ventions, provid<strong>in</strong>g<br />
fi nance to develop technology and venture<br />
capital for <strong>the</strong> exploitation <strong>the</strong>reof.<br />
- - 4 361 4 464 4 361 4 464 The company sources technologies and<br />
entrepreneurs from <strong>the</strong> <strong>CSIR</strong>, o<strong>the</strong>r S&T <strong>in</strong>stitutions,<br />
universities or any developer of technology and<br />
develops <strong>the</strong>se <strong>in</strong>to viable bus<strong>in</strong>esses with <strong>the</strong><br />
aim of sp<strong>in</strong>n<strong>in</strong>g <strong>the</strong>m off for capital ga<strong>in</strong> and/or<br />
public good.<br />
- - 4 727 4 800 5 185 5 153 The pr<strong>in</strong>cipal activity of <strong>the</strong> company is that of<br />
consult<strong>in</strong>g on technology audit<strong>in</strong>g, technology<br />
evaluation and technology transfer on behalf of<br />
clients <strong>in</strong> <strong>the</strong> public and private sectors.<br />
- - 21 088 22 526 26 196 27 529<br />
The company manufactures and distributes high<br />
technology cameras for use <strong>in</strong> detect<strong>in</strong>g faults on<br />
overhead electricity distribution l<strong>in</strong>es.<br />
The pr<strong>in</strong>cipal activities of <strong>the</strong> company are to<br />
develop, commercialise and market naturally<br />
derived products for <strong>the</strong> biotechnology and<br />
pharmaceutical markets.<br />
167 ANNUAL FINANCIAL STATEMENTS